ANXIOUS DEPRESSION. Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University
|
|
- Jasmin Woods
- 6 years ago
- Views:
Transcription
1 ANXIOUS DEPRESSION Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University
2 NED H. KALIN, MD Disclosures!! Research/Grants: None!! Speakers Bureau: None!! Consultant: None!! Stockholder: Corcept Therapeutics; CeNeRx BioPharma!! Other Financial Interest: Owner of Promoter Neurosciences, LLC; holds patents for the following: promoter sequences for corticotropin-releasing factor CRF2alpha and method of identifying agents that alter the activity of the promoter sequences (U.S. Patent issued on ; patent # , U.S. Patent issued on ; patent #7,531,356); promoter sequences for urocortin II and the use thereof (U.S. Patent issued on ; patent # ); and promoter sequences for corticotropinreleasing factor binding protein and use thereof (U.S. Patent issued on ; patent # )!! Advisory Board: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; CeNeRx BioPharma; CME Outfitters, LLC; Corcept Therapeutics; Eli Lilly and Company; Elsevier; Letters & Sciences; Medivation, Inc.; Otsuka America Pharmaceuticals; Sanofi-Aventis; Wyeth Pharmaceuticals
3 ALAN F. SCHATZBERG, MD Disclosures!! Research/Grants: None!! Speakers Bureau: None!! Consultant: BrainCells Inc.; CeNeRx BioPharma; Corcept Therapeutics; CNS Response, Inc.; Eli Lilly and Company; GlaxoSmithKline; Neuronetics Inc.; PharmaNeuroBoost; Sanofiaventis; Takeda Pharmaceuticals North America, Inc.!! Stockholder: Amnestix, Inc.; BrainCells Inc.; CeNeRx BioPharma; Corcept Therapeutics; Forest Laboratories, Inc.; Merck & Co., Inc.; Neurocrine Biosciences, Inc.; Pfizer Inc.; PharmaNeuroBoost; Somaxon; Synosis!! Other Financial Interest: Named inventor on pharmacogenetic use patents on prediction of antidepressant response and use of glucocorticoid antagonists!! Advisory Board: None
4 LEARNING OBJECTIVE Employ strategies for improved recognition and management of anxious depression
5 ANXIOUS DEPRESSION (AD)!! Symptoms of anxiety are common among individuals with Major Depressive Disorder!! Presence of anxiety with depression is associated with poorer treatment outcomes and greater risk of suicide!! Underlying commonalities between MDD and Generalized Anxiety Disorder suggest they may reflect the same phenomenon 1,2,3,4 and are not distinct entities!! Shared genetic factors!! Shared temperament (i.e., negative affectivity)!! Treatment response (i.e., SSRIs) References available in supplemental bibliography.
6 ANXIOUS DEPRESSION (AD)!!Mixed Anxiety and Depression is present in DSM-IV s Appendix and in ICD-10 but are defined somewhat differently!!dsm-v Mood Disorders Work Group is proposing recognition of AD as a clinically significant syndrome!!may help physicians (esp. PCPs) better identify and treat these patients!!may increase compatibility between U.S. and international definitions of AD American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association 2000.
7 PROPOSED DSM-V CRITERIA FOR AD!! Presence of 3 or 4 symptoms of major depression (including depressed mood and/or anhedonia)!! Must be accompanied by anxious distress!!defined as having two or more of the following symptoms: irrational worry, preoccupation with unpleasant worries, having trouble relaxing, motor tension, fear that something awful may happen!! Present for at least two weeks!! No other depressive or anxiety disorder is present Proposed criteria available at MoodDisorders.aspx.
8 PROPOSED DSM-V CRITERIA FOR AD (CONT.)!!Will include a dimension of severity to help answer questions about course, stability, and prognosis!!will be examined in DSM-V field trials in large, academic-medical institutions!!later field trials that include primary care settings may offer additional insight into the reliability of the criteria Proposed criteria available at MoodDisorders.aspx.
9 ANXIOUS DEPRESSION Categorical vs. Dimensional Definitions Major Depressive Disorder Anxious Depression: MDD with anxiety comorbidity Anxiety Disorders Depression Anxious Depression: HAM-D-17 Anxiety/ Somatization Score > 6 Anxiety HAM-D = Hamilton Depression Rating Scale, MDD = major depressive disorder
10 ANXIOUS DEPRESSION Clinical and Demographic Characteristics!!Greater severity of illness 1!!Younger mean age 2!!Earlier age of onset 2!!20.6 ± 10.4 years in MDD with comorbid anxiety disorders!!28.4 ± 13.0 years in MDD alone 1. Joffe RT, et al. Am J Psychiatry 1993;150: Fava M, et al. Compr Psychiatry 2000;41:
11 ANXIOUS DEPRESSION Course of Illness!!Chronicity is common 1!!Greater functional impairment 2!!Increased risk of suicide 3!!Greater chance of treatment discontinuation 4 1. Van Valkenburg C, et al. J Clin Psychiatry 1984;45: Joffe RT, et al. Am J Psychiatry 1993;150: Clayton P, et al. Am J Psychiatry 1991;148: Flint AJ, Rifat SL. Am J Geriatr Psychiatry 1997;5:
12 HOW DOES ANXIOUS DEPRESSION RESPOND TO ANTIDEPRESSANT TREATMENT?!!Possible diminished response to antidepressant treatment!!in adults 1!!In elderly 2!!When anxiety persists despite response, greater likelihood of relapse 3 1. Fava M, et al. Biol Psychiatry 1997;42: Flint AJ, Rifat SL. Am J Geriatr Psychiatry 1997;5: Flint AJ, Rifat SL. Psychiatry Res 1997;66:23-31.
13 REMISSION RATES FOLLOWING CITALOPRAM TREATMENT IN LEVEL 1 OF STAR*D 40% 35% Remission Rate 30% 25% 20% 15% 10% 5% * 0% Anxious Depression N = 2,876 * p <.05 Fava M, et al. Am J Psychiatry 2008;165: Non-Anxious Depression
14 REMISSION RATES (HAM-D-17 < 8) IN LEVEL 2 OF STAR*D Anxious vs. Non-Anxious MDD 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% * p <.05 Anxious MDD * * Non-Anxious MDD Fava M, et al. Am J Psychiatry 2008;165: * * BUP SER VEN BUP AUGM BUSP AUGM n = 239 n = 238 n = 250 n = 279 n = 286 *
15 ANXIOUS DEPRESSION Treatment Approaches!!Monotherapy with antidepressants!!sedating vs. nonsedating!!augmentation with:!!benzodiazepines 1!!Eszopiclone 2!!Buspirone 3!!Gabapentin or other anticonvulsants 1!!Antipsychotics 5 1. Davidson JR. J Clin Psychiatry 2010;71[suppl E1]:e04.; 2. Fava M, et al. Poster 146 at The American College of Neuropsychopharmacology 2008, Scottsdale, AZ.; 3. Fava M, et al. Am J Psychiatry 2008;165: ; 4. Nemeroff CB. J Clin Psychiatry 2005;66:13-21.
16 USE OF ANXIOLYTICS AND HYPNOTICS DURING SSRI TREATMENT Drug No. of Patients Hypnotic % Hypnotic/ Anxiolytic % Paroxetine 5, Sertraline 13, Fluoxetine 12, From the Texas Medicaid Database Rascati K. Clin Ther 1995;17:
17 ANXIOUS DEPRESSION Management Issues!!Antidepressant monotherapy works well in efficacy trials!!concerns about agitation/activation often lead to the use of:!!relatively more sedating antidepressants!!lower starting doses!!polypharmacy (e.g., combination of an antidepressant and a benzodiazepine)!!higher antidepressant doses may be required in some patients
18 ANXIOUS DEPRESSION Management Issues (Cont.)!!Anxiety sensitivity may predict poorer treatment adherence 1!!Side effect management very important!!concomitant anti-anxiety drugs can be started with the antidepressant or added later!!what is the role of psychotherapy? 1. Tedlow JR, et al. Biol Psychiatry 1996;40:
19 SUMMARY!! A common presentation of the many subtypes of depression!! May explain the inability to achieve the expected rates of remission and recovery in the majority of patients with depression!! Has greater morbidity and mortality compared to depression without anxiety if not identified and adequately treated!! Antidepressants are typically equally effective in anxious depression!! Overall efficacy of currently available therapies is modest!! Anxiolytics may be indicated as adjuncts in nonresponders
20
Age / Sex: Presenting Problem:
William E. Bunney, Jr., MD, and Ned H. Kalin, MD Chart Review: Anxious Depression PATIENT INFO 17 / Female Age / Sex: Presenting Problem: DA is 17 y/o women who presented with intermittent symptoms of
More informationMood and Anxiety Disorders: The Complexities of Integrating Syndromes
Mood and Anxiety Disorders: The Complexities of Integrating Syndromes Ned Kalin, MD University of Wisconsin School of Medicine Martin B. Keller, MD Brown Medical School David R. Rubinow, MD University
More informationPSYCHOTIC MAJOR DEPRESSION
PSYCHOTIC MAJOR DEPRESSION Alan F. Schatzberg, MD Kenneth T. Norris, Jr. Professor Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine Stanford, CA PSYCHOTIC MAJOR DEPRESSION
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 1 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Best Practices in the Management of Geriatric Depression Sarah Hollingsworth Lisanby, MD Duke University School of Medicine Durham, NC
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 2 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationThe scope of the problem. Literature review
Past Year: Novartis Ever: Alkermes, Amylin, Behringer- Ingelheim, Biovail, Bristol-Myers Squibb, Eli Lilly, Embryon, GlaxoSmithKline, Merck, Organon, Park-Davis, Pfizer, Sanolfi-Aventis, Smith-Kline Beacham,
More informationDecember 2014 MRC2.CORP.D.00011
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. advice or professional diagnosis. Users seeking
More informationIs It Insomnia, Is It Hypersomnia, Is It Both? W. Vaughn McCall, MD, MS Wake Forest University Health Sciences
Is It Insomnia, Is It Hypersomnia, Is It Both? W. Vaughn McCall, MD, MS Wake Forest University Health Sciences W. Vaughn McCall, MD, MS Disclosures Research/Grants: Mini-Mitter Co.; National Institute
More informationPharmacological treatment of anxiety disorders where is
Pharmacological treatment of anxiety disorders where is the room for improvement? David S Baldwin, Professor of Psychiatry BAP Masterclass, 15 th April 2011 dsb1@soton.ac.uk Declaration of interests (last
More informationMeasurement-based Scales in Major Depressive Disorder:
This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka Pharmaceutical Development and Commercialization, Inc.
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationABSTRACT ORIGINAL RESEARCH. Roger S. McIntyre. Emmanuelle Weiller
Adv Ther (2015) 32:429 444 DOI 10.1007/s12325-015-0207-3 ORIGINAL RESEARCH Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response
More informationANXIETY DISORDERS IN THE ELDERLY IMPACT OF LATE-LIFE ANXIETY CHANGES IN DSM-5 THE COSTS 6/4/2015 LATE-LIFE ANXIETY TOPICS TO BE COVERED
LATE-LIFE ANXIETY TOPICS TO BE COVERED ANXIETY DISORDERS IN THE ELDERLY Dr. Lisa Talbert Classes of Anxiety Disorders Diagnosis Comorbidities Pharmacologic Management Psychological Management LATE LIFE
More informationLinda Carpenter, M.D.
Stress, Depression and Physical Health Linda Carpenter, M.D. Associate Professor of Psychiatry and Human Behavior and Medicine Alpert Medical School of Brown University Chief, Butler Hospital Mood Disorders
More informationStahl s Illustrated. Mood Stabilizers. Stephen M. Stahl. University of California at San Diego. Nancy Muntner. Illustrations. Sara Ball.
Stahl s Illustrated Mood Stabilizers University of California at San Diego Nancy Muntner Illustrations Sara Ball Editor c a m b r i d g e university pr e s s Cambridge, New York, Melbourne, Madrid, Cape
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationDepression in the Medically Ill
Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College
More informationORIGINAL RESEARCH. Brain Stimulation (2010) 3,
Brain Stimulation (2010) 3, 187 99 www.brainstimjrnl.com ORIGINAL RESEARCH Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationAtoms, represents a relatively common depressive subtype.
Bupropion Versus SSRIs in Anxious Depression Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the Treatment of Major Depressive Disorder With High Levels of Anxiety (Anxious Depression):
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationPatients with major depressive disorder often also suffer
Article Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report Maurizio Fava, M.D. A. John Rush, M.D. Jonathan E. Alpert, M.D., Ph.D. G.K. Balasubramani,
More informationAnxiety Disorders. Fear & Anxiety. Anxiety Disorder? 26/5/2014. J. H. Atkinson, M.D. Fear. Anxiety. An anxiety disorder is present when
Anxiety s J. H. Atkinson, M.D. HIV Neurobehavioral Research Center University of California, San Diego Department of Psychiatry & Veterans Affairs Healthcare System, San Diego Materials courtesy of Dr.
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationA PATIENT-CENTERED APPROACH TO THE MANAGEMENT OF DEPRESSION
Education Partner A PATIENT-CENTERED APPROACH TO THE MANAGEMENT OF DEPRESSION November 15, 212 Boston, Massachusetts Session 3: A Patient-Centered Approach to the Management of Depression: Achieving and
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationTreatment Resistant Depression: A Systematic Approach to Management
Treatment Resistant Depression: A Systematic Approach to Management Michael E. Thase, M.D. University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More informationDo the Right Thing: Good Clinical Practice for Clinical Research
Do the Right Thing: Good Clinical Practice for Clinical Research Andrew A. Nierenberg, MD Director, Bipolar Clinic and Research Program, Director, Training and Education, MGH Research Institute Massachusetts
More informationObsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care
Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,
More informationForty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
Adelaide Robb, MD Associate Professor Psychiatry and Pediatrics Source Advisory Board Disclosure Speaker s Bureau Bristol Myers Squibb Yes Yes Yes Epocrates Research Contract Royalties Yes Stock Janssen
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by New and Emerging Antidepressant Strategies in MDD Alan F. Schatzberg, MD Stanford University School of Medicine Stanford,
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationRecognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD)
Objectives Recognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD) Discuss the burden of MDD on the individual and society Explore the negative impact of residual symptoms Identify
More informationcontrols past MDD current MDD
인제대학교서울백병원김원 * decreased appetite * decreased sleep * psychomotor agitaion * poor concentraion * psychomotor retardation * anhedonia depressed mood * low energy * guilt suicidal ideation * < 0.05 * total
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationDiabetes and Depression. Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C
Diabetes and Depression Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C 2008 Learning Objectives State the risk factors for depression Identify the vulnerability
More informationCognitive Impairment in Major Depressive Disorder as a Target for Drug Development
Cognitive Impairment in Major Depressive Disorder as a Target for Drug Development Maurizio Fava, MD Director Clinical Research Program Executive Vice Chair Department of Psychiatry Executive Director
More informationMale Sexual Dysfunction in Psychiatric Illnesses Sujit Kumar Kar 1, Saranya Dhanasekaran 1 Correspondence: gmail.
RESEARCH ARTICLE Open Access Male Sexual Dysfunction in Psychiatric Illnesses Sujit Kumar Kar 1, Saranya Dhanasekaran 1 Correspondence: drsujita@gmail.com; saranya296@ gmail.com Full list of author information
More informationTreatment of Anxiety (without benzos)
Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common
More informationCHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...
More informationINSIGHTS INTO ADDRESSING EARLY SCHIZOPHRENIA: PRODROME AND FIRST EPISODE
INSIGHTS INTO ADDRESSING EARLY SCHIZOPHRENIA: PRODROME AND FIRST EPISODE S. Charles Schulz, MD Professor & Head Donald W. Hastings Endowed Chair Department of Psychiatry University of Minnesota Medical
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationAdvances in Diagnosis, Neurobiology, and Treatment of Mood Disorders
Advances in Diagnosis, Neurobiology, and Treatment of Mood Disorders June 13-14, 2016 Field House Coral Gables University of Miami Coral Gables, FL Management of Depression in the Geriatric Patient Samir
More informationCurrent. p SYCHIATRY. Treatment-resistant. Switch or augment? Choices that
Treatment-resistant Switch or augment? Choices that depression improve response rates When initial antidepressant therapy fails, an algorithmic approach to medication is more effective than treatment-as-usual.
More informationANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN
UW PACC Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL
More informationObjectives. Sexual dysfunction (SD) SD in the general population. Assessment of sexual functioning ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION
Objectives To appreciate the relationship between major depressive disorder, its treatment and sexual dysfunction To review the assessment of sexual function An approach to the clinical management of antidepressant
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More informationAge / Sex: 31-year-old bi-racial male admitted to hospital through. Background:
Stephen M. Goldfinger, MD Chart Review: The Patient You Hate to Treat PATIENT INFO 31 / Male Age / Sex: 31-year-old bi-racial male admitted to hospital through Background: Psychiatric Emergency Services.
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationAdherence in A Schizophrenia:
Understanding and Diagnosing Bipolar Disorder Treatment Promoting for Bipolar Treatment Disorder Adherence in A Schizophrenia: Resource for Providers Engagement Strategies for Health Care Providers, Case
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationNon-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450
James A. Bourgeois, O.D., M.D. Vice Chair Clinical Affairs and Director, CL Service University of California San Francisco Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 Localize! Sequence! 1
More information1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.
1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,
More informationSession 3: Help Me, Doc - I ve Got High Anxiety! Learning Objectives
Session 3: Help Me, Doc - I ve Got High Anxiety! Learning Objectives 1. Recognize the distinguishing features of common anxiety disorders seen in primary care. 2. Use screening measures for diagnosis of
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationAntidepressant Medication Therapy in Primary Care July 25, 2013
New York State Collaborative Care Initiative Antidepressant Medication Therapy in Primary Care July 25, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More information#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by #CHAIR2016 Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders Alan F. Schatzberg,
More informationManaging Anxiety Disorder in Primary Care
Saturday General Session Managing Anxiety Disorder in Primary Care Chris Ticknor, MD Private Practice, Psychiatry Adjunct Professor of Psychiatry UT Health Science Center at San Antonio San Antonio, Texas
More informationBipolar Depression Update 2015
Bipolar Depression Update 2015 Andrew A. Nierenberg, MD Thomas P. Hackett, MD, Chair in Psychiatry Director, Bipolar Clinic and Research Program Massachusetts General Hospital Professor of Psychiatry,
More informationWith Adult Major Depressive Disorder: A Clinical and Economic Assessment
Atypical Antipsychotics to Achieve Remission With Adult Major Depressive Disorder: A Clinical and Economic Assessment Charles L. Raison, MD Associate Professor Department of Psychiatry University of Arizona
More informationStart Low, Go Slow but Treat to Target
Start Low, Go Slow but Treat to Target Pharmacotherapy for Depression, Anxiety and At-Risk Alcohol Use in Late Life September 29, 2014 Audio and Control Panel instruction On the phone? Raise your hand
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More informationLife is a miserable thing. I have decided to spend my life thinking about it. Irvin D. Yalom, The Schopenhauer Cure
Life is a miserable thing. I have decided to spend my life thinking about it. Irvin D. Yalom, The Schopenhauer Cure GERIATRIC DEPRESSION Samir Patel, MD Geriatrics and Palliative Medicine and Geriatric
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationHHS Public Access Author manuscript Bipolar Disord. Author manuscript; available in PMC 2016 June 01.
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression Dawn F Ionescu a,b, David A Luckenbaugh c, Mark J Niciu c, Erica M Richards c, and Carlos A Zarate Jr
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationThe Context: Why is this so important to treat?
ER Management of Depression for PGY1s Ian A. Cook, M.D. Director, UCLA Depression Research Program UCLA Department of Psychiatry Laboratory of Brain, Behavior, and Pharmacology Semel Institute for Neuroscience
More informationPanic disorder is a chronic and recurrent illness associated
CLINICAL PRACTICE GUIDELINES Management of Anxiety Disorders. Panic Disorder, With or Without Agoraphobia Epidemiology Panic disorder is a chronic and recurrent illness associated with significant functional
More informationMajor depressive disorder (MDD) is the most prevalent. Clinical Guidelines
Clinical Guidelines Annals of Internal Medicine Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians Gerald Gartlehner, MD, MPH;
More informationDtients experience a chronic course, and 75% to 80% of patients
Kaymaz et al. Evidence That Patients With Single Versus Recurrent Depressive Episodes Are Differentially Sensitive to Treatment Discontinuation: A Meta-Analysis of Placebo-Controlled Randomized Trials
More informationManaging Depression as a Chronic Condition. D. Green MD TOH/Bruyere Shared Care Program
Managing Depression as a Chronic Condition D. Green MD TOH/Bruyere Shared Care Program None Financial disclosure Objectives To review key concepts relevant to understanding the course of depression To
More informationWest Virginia University School of Medicine, Morgantown, West Virginia
MARY CARROLL SHEMO, M.D., D.F.A.P.A. CURRICULUM VITAE Psychiatric Alliance of the Blue Ridge Office: (434) 984-6777 First Floor, Old Ivy Commons, 2496 Old Ivy Road, Suite 400 Fax: (434) 296-1412 22903-4895
More informationTargets of Psychopharmacological Drug Action
Targets of Psychopharmacological Drug Action (page 33 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry University of California, San Diego School of Medicine Honorary
More informationJune 2015 MRC2.CORP.D.00030
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. June 2015 MRC2.CORP.D.00030 advice or professional
More informationWhat s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry
What s New in Depression in 2016? By: Phyliss Nicole Taylor, MD UF Health Jacksonville Psychiatry New Depression Screening Guidelines US Preventive Services Task Force (USPSTF) updated its 2009 recommendations
More informationThe following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online.
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by an educational
More information48 th Annual Meeting. Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5. Disclosure. Depression. Patient Case. Objectives 7/19/2014
48 th Annual Meeting Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Published in 2013 Most published treatment guidelines
More informationBipolar Depression: Engaging the Patient. Mark Frye, MD Mayo Clinic Rochester, MN
Bipolar Depression: Engaging the Patient Mark Frye, MD Mayo Clinic Rochester, MN Mark Frye, MD Disclosures Research/Grants: AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationDepression Management in Healthcare Systems: A Team Approach to Care
SYLLABUS AND COURSE GUIDE Release Date: February 23, 2009 Credit Expiration Date: February 23, 2010 WC-006-022309-07 Depression Management in Healthcare Systems: A Team Approach to Care A Free, One-Hour
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Age as factor in selective mutism, 623 as factor in social phobia, 623 Agoraphobia, 593 600 described, 594 596 DSM-V changes related to,
More informationTreating Depression in Disadvantaged Women: What is the evidence?
Treating Depression in Disadvantaged Women: What is the evidence? Megan Dwight Johnson, MD MPH Associate Professor Medical Director, UWMC Inpatient Psychiatry Department of Psychiatry and Behavioral Sciences
More informationBipolar Depression Update 2016
Bipolar Depression Update 2016 Andrew A. Nierenberg, MD Thomas P. Hackett, MD, Endowed Chair in Psychiatry Director, Bipolar Clinic and Research Program Massachusetts General Hospital Professor of Psychiatry,
More informationORIGINAL ARTICLE. Trial Registration: clinicaltrials.gov Identifier: NCT
ORIGINAL ARTICLE Cognitive Behavioral Analysis System of Psychotherapy and Brief Supportive Psychotherapy for Augmentation of Antidepressant Nonresponse in Chronic Depression The REVAMP Trial James H.
More informationFive Changes in DSM 5 Principles for Primary Care. Tom Janzen, M.D. STEGH Mental Health May 14, 2014
Five Changes in DSM 5 Principles for Primary Care Tom Janzen, M.D. STEGH Mental Health May 14, 2014 Overall Learning Objectives Review 5 changes to DSM 5 which have significance for Family Physicians Examine
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More information